Analyzing Kalaris Therapeutics (NASDAQ:KLRS) and Cardium Therapeutics (OTCMKTS:CRXM)

Cardium Therapeutics (OTCMKTS:CRXM) and Kalaris Therapeutics (NASDAQ:KLRS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.

Earnings & Valuation

This table compares Cardium Therapeutics and Kalaris Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardium Therapeutics	N/A	N/A	N/A	N/A	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44 million	($4.21)	-1.28

Analyst Ratings

This is a summary of current ratings and target prices for Cardium Therapeutics and Kalaris Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardium Therapeutics	0	0	0	0	0.00
Kalaris Therapeutics	1	1	3	1	2.67

Kalaris Therapeutics has a consensus price target of $14.00, indicating a potential upside of 159.74%. Given Kalaris Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Kalaris Therapeutics is more favorable than Cardium Therapeutics.

Insider and Institutional Ownership

66.1% of Kalaris Therapeutics shares are owned by institutional investors. 49.8% of Cardium Therapeutics shares are owned by company insiders. Comparatively, 75.0% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Cardium Therapeutics and Kalaris Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardium Therapeutics	N/A	N/A	N/A
Kalaris Therapeutics	N/A	-73.11%	-43.56%

Summary

Kalaris Therapeutics beats Cardium Therapeutics on 6 of the 8 factors compared between the two stocks.

About Cardium Therapeutics

Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.

About Kalaris Therapeutics

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.